Annaliesa Anderson | Chief Scientific Officer, Bacterial Vaccines and the Hospital Business Unit, Pfizer

Annaliesa Anderson, Chief Scientific Officer, Bacterial Vaccines and the Hospital Business Unit, Pfizer, Pfizer

Annaliesa Anderson PhD FAAM, has over 20 years of pharmaceutical research experience and is currently the Chief Scientific Officer for Bacterial Vaccines at Pfizer Inc. Her responsibilities include infectious disease vaccine R and D, surveillance and the assessment of the immunopathology of bacterial colonization and disease. Dr Andersons experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Neisseria meningitidisStaphylococcus aureus and Clostridium difficile and Enterococcus sp. In this role, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept and recently the licensure of the N. meningitidis serogroup B vaccine Trumenba®.


April 15 Plenary Congress Day 1 @ 15:30

Fire chat: The future of the vaccine business from the executives

  • What vaccines will they invest in and why
  • How will we translate data heavy tools into translational precision medicines?
  • Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs?
  • Should it be industry’s responsibility to help address vaccine hesitancy?
last published: 26/Mar/19 17:35 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071